CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment-Reference-Cited by-同舟云学术

CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment

Published:2016-03-16 Issue:16 Volume:86 Page:1553-1556
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Cao Yonghao,Nylander Alyssa,Ramanan Sriram,Goods Brittany A.,Ponath Gerald,Zabad Rana,Chiang Veronica L.S.,Vortmeyer Alexander O.,Hafler David A.,Pitt David

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference7 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

3. Nivolumab plus Ipilimumab in Advanced Melanoma

4. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis

5. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors;Biomedicines;2024-06-13

2. Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation;Science Translational Medicine;2024-06-12

3. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

4. Neuropsychological issues related to immunotherapy;Neuropsychological and Psychosocial Foundations of Neuro-Oncology;2024

5. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders;Current Neurology and Neuroscience Reports;2023-10-23